Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
Nicole A CarreauOrrin PailPhilippe ArmandReid MerrymanRanjana H AdvaniMichael A SpinnerAlex HerreraRobert ChenSarah TomassettiRadhakrishnan RamchandrenMuhammad S HamidSarit AssoulineRaoul SantiagoNina Wagner-JohnstonSuman PaulJakub SvobodaSteven BairStefan BartaYang LiuSunita NathanReem KarmaliMadelyn BurkartPallawi TorkaKevin DavidCatherine WeiFrederick LansiganLukas EmeryDaniel PerskySonali SmithJames GodfreyJulio ChavezYuhe XiaAndrea B TroxelCatherine S DiefenbachPublished in: The oncologist (2020)
Novel, life-prolonging treatment strategies in relapsed and refractory (R/R) Hodgkin lymphoma (HL) are greatly desired. The results of this multicenter analysis concur with a smaller, earlier report that checkpoint blockade therapy (CBT) use in R/R HL may sensitize patients to their subsequent treatment. This approach may potentially enhance therapeutic options or to bridge patients to transplant. Prospective data are warranted prior to practice implementation. As more work is done in this area, we may also be able to optimize sequencing of CBT and novel agents in the treatment paradigm to minimize treatment-related toxicity and thus improve patient quality of life.
Keyphrases
- hodgkin lymphoma
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- primary care
- chronic kidney disease
- clinical trial
- dna damage
- oxidative stress
- stem cells
- combination therapy
- peritoneal dialysis
- diffuse large b cell lymphoma
- cell cycle
- acute myeloid leukemia
- quality improvement
- case report
- single cell
- deep learning